Search all trials

Find therapies in clinical trials near you – page 17

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Neoplasm

Not recruiting

Registered drugNo placebo

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Registered drug

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drug

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Gastric cancer

Not recruiting

Registered drug

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Bemarituzumab

Contact Research Centre

Plasma cell myeloma

Not recruiting

InvestigationalNo placebo

Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

K-ras gene mutation+1

Not recruiting

InvestigationalNo placebo

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Gastrooesophageal cancer+5

Not recruiting

Registered drug

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Registered drug

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Olaparib

Contact Research Centre

Giant cell arteritis

Not recruiting

Registered drugNo placebo

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Folic Acid

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Registered drug

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone

Contact Research Centre

Find therapies in clinical trials near you – page 17

261 trials match your criteria

Neoplasm

Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

Bladder transitional cell carcinoma

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Non-small cell lung cancer

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Gastric cancer

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Plasma cell myeloma

Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Triple negative breast cancer

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

K-ras gene mutation+1

Study of adagrasib in elderly patients (70 years or older) or patients with poor performance status who have KRAS G12C mutation-positive non-small cell lung cancer

Gastrooesophageal cancer+5

Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer

HER2 positive breast cancer

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Breast cancer

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Giant cell arteritis

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Prostate cancer metastatic

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.